Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
LOS ANGELES, Oct. 18, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (Nasdaq:ICPT) concerning possible violations of federal securities laws between May 31, 2016 and September 20, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the November 27, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements, and/or failed to disclose, that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis (“PBC”). As a result, the Company’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug. When this news was announced, Intercept’s stock price fell materially, which caused investors harm according to the lawsuit.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/
